Health tech company myTomorrows has launched a dedicated platform to help BioPharma firms manage expanded access programs more efficiently—reducing regulatory delays and getting treatments to patients faster.

myTomorrows has introduced an AI-enabled SaaS platform designed to simplify the complex and often fragmented management of expanded access (EA) programs for BioPharma companies.

Expanded access pathways allow physicians to request investigational treatments for patients with serious or life-threatening conditions when no other options exist. However, navigating the regulatory requirements, documentation processes, and cross-border compliance issues often creates significant delays—hindering access and limiting real-world data collection.

The newly launched platform is built to tackle these barriers head-on. Drawing on more than a decade of operational experience, the solution enables BioPharma teams to manage EA requests and programs independently—while remaining compliant with global regulatory frameworks. It supports both structured programs and urgent ad-hoc requests, with flexible configurations to match internal capabilities and program complexity.

Key features include centralized case tracking, customizable workflows, physician communication tools, integrated analytics, and embedded global regulatory intelligence. Companies can use the platform autonomously or combine it with optional strategic support from myTomorrows—creating a hybrid approach tailored to operational needs.

“For too long, BioPharma companies have lacked the infrastructure to manage expanded access efficiently and consistently across borders,” said Michel van Harten, CEO of myTomorrows. “Our new platform changes that. It gives companies a purpose-built system to streamline processes, ensure regulatory compliance, and ultimately bring emerging therapies to patients faster.”

The platform has already been integrated into myTomorrows’ own international operations and is designed to meet the evolving needs of BioPharma partners and frontline clinicians. According to the company, over 50 BioPharma organizations currently work with its EA services globally.

The launch also supports broader goals of improving pre-approval treatment access, particularly in regions where commercial timelines lag. By reducing operational friction and facilitating the capture of real-world data, the platform aims to accelerate time-to-treatment and support more informed regulatory and market access decisions.

myTomorrows is ISO 27001 certified and operates in compliance with both GDPR and HIPAA standards, supporting secure data management throughout the EA lifecycle.